← Leaderboards
Imre Noth
University Of Virginia
$12,167,659
Attributed
$19,120,895
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,120,895 · 8
By mechanism
UH3$11,596,602 · 1
R01$4,567,688 · 2
RC1$1,000,000 · 1
UG3$976,537 · 1
U10$969,827 · 1
M01$10,241 · 2
Top collaborators
- Fernando J Martinez7 shared
- Naftali Kaminski2 shared
- Dan Liviu Nicolae2 shared
Most similar at University Of Virginia
Same institution · by research overlap
- John S Kim$1,503,057
- Yun Michael Shim$6,424,060
- Kun Qing$2,843,545
- William Gerald Teague$5,830,751
- Justin S. Hanes$23,093,683
Others in their field
Top investigators on “Cohort”
- David R. Weir · University Of Michigan At Ann Arbor$406,814,098
- George R Seage · Abt Associates, Inc.$297,656,361
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$242,146,554
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
CohortVariantGenetic VariantBloodGenotypeTollip GenePhenotypeProteomicsSamplingMolecular MarkerGeneticPulmonary FibrosisGenesLinkPharmacogenomicsCollectionProteinsIdiopathic Pulmonary FibrosisLungInterstitial Lung DiseasesDouble-Blind MethodRandomizedGene ProteinsPlacebos
Grant awards (22)
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$1,085,815
UH3 · FY2025 · HL
The role of quantitative CT and radiomic biomarkers for precision medicine in pulmonary fibrosis$731,520
R01 · FY2025 · HL · contact PI
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$1,110,651
UH3 · FY2024 · HL
The role of quantitative CT and radiomic biomarkers for precision medicine in pulmonary fibrosis$762,272
R01 · FY2024 · HL · contact PI
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$132,310
UH3 · FY2024 · HL
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$3,032,451
UH3 · FY2023 · HL
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$3,487,084
UH3 · FY2022 · HL
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$2,748,291
UH3 · FY2021 · HL
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$976,537
UG3 · FY2019 · HL
Architectural structure and regulation of TOLLIP in IPF$734,238
R01 · FY2019 · HL · contact PI
Architectural structure and regulation of TOLLIP in IPF$770,633
R01 · FY2018 · HL · contact PI
Architectural structure and regulation of TOLLIP in IPF$795,038
R01 · FY2017 · HL · contact PI
Architectural structure and regulation of TOLLIP in IPF$773,987
R01 · FY2016 · HL · contact PI
Genome-Wide Association and Exon Sequencing Study in IPF$500,000
RC1 · FY2010 · HL · contact PI
Genome-Wide Association and Exon Sequencing Study in IPF$500,000
RC1 · FY2009 · HL · contact PI
Combination Therapy in IPF$202,819
U10 · FY2009 · HL · contact PI
Combination Therapy in IPF$193,152
U10 · FY2008 · HL · contact PI
Combination Therapy in IPF$191,532
U10 · FY2007 · HL · contact PI
FP AND SALMETEROL IN PREVENTING COPD EXACERBATIONS$1,124
M01 · FY2007 · RR · contact PI
Combination Therapy in IPF$191,699
U10 · FY2006 · HL · contact PI
FP AND SALMETEROL IN PREVENTING COPD EXACERBATIONS$9,117
M01 · FY2006 · RR · contact PI
Combination Therapy in IPF$190,625
U10 · FY2005 · HL